Gilead Sciences, Inc. (GILD) Stock Price Today
24H
1W
1M
3M
YTD
1Y
5Y
Overview
Financial
Technicals
Analysis
Corporate Action
About
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Technical Indicators
|
|
|
Overall Summary
Bearish (10)Neutral (6)Bullish (11)
Performance
GILD ROI
+31.98%% from 52W High-5.8%
52W Low: $89.14
08 Jan 2025
52W High: $128.07
19 Nov 2025
News
US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions
Let’s trade or invest in this asset by signing up or logging in!
You can also download our app!
